Evidence map›Paper›PMID 32372223›Full record

ArticleVirchows Archiv : an international journal of pathology2020

Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis.

Béla Tóth, Norbert Kiss, Judit Hársing, Sarolta Kárpáti, Judit Csomor, Csaba Bödör, József Tímár, Erzsébet Rásó

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Béla TóthDepartment of Dermatology, Venereology and Dermatooncology, Semmelweis University, 41 Mária utca, Budapest, H-1085, Hungary. dr.toth.bela@gmail.com.ORCID https://orcid.org/0000-0003-0498-0387
Norbert KissDepartment of Dermatology, Venereology and Dermatooncology, Semmelweis University, 41 Mária utca, Budapest, H-1085, Hungary.
Judit HársingDepartment of Dermatology, Venereology and Dermatooncology, Semmelweis University, 41 Mária utca, Budapest, H-1085, Hungary.
Sarolta KárpátiDepartment of Dermatology, Venereology and Dermatooncology, Semmelweis University, 41 Mária utca, Budapest, H-1085, Hungary.
Judit Csomor1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Csaba Bödör1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
József Tímár2nd Department of Pathology, Semmelweis University, Budapest, Hungary.
Erzsébet Rásó2nd Department of Pathology, Semmelweis University, Budapest, Hungary.
Semmelweis University · HU

Funding

Nemzeti Kutatási Fejlesztési és Innovációs Hivatal NOTKA 114460Nemzeti Kutatási Fejlesztési és Innovációs Hivatal NVKP-16-1-2016-004
6 · The paper itself

Abstract

Langerhans cell histiocytosis (LCH) is characterized by mutations of the RAS-RAF-MAPK signaling pathway. We analyzed MAP2K1, NRAS and KIT mutation incidence in skin lesions of BRAF wild-type (wt) LCH patients. We evaluated the occurrence of MAP2K1, NRAS and KIT mutations in seven LCH and one indeterminate cell histiocytosis (ICH) patients. MAP2K1 mutation frequency was found to be 3/7 (42.9%) in LCH and also found in ICH. Similarly, the KIT mutation frequency was found to be equally prevalent (4/7, 57.1%) in LCH and also occurred in ICH. Involvement of KIT exons in LCH-ICH indicated that exon 9/11/18 were equally prevalent followed by exon 13. This exploratory analysis on BRAF-wt LCH revealed a KIT mutation rate comparable to MAP2K1. Although the detected KIT mutations are different from activating mutations found in other KIT-dependent neoplasms, our data suggest that KIT-inhibitors might have a role in treating BRAF-wt LCH patients.

Indexed as

MutationAdolescentAdultAgedFemaleGenetic Predisposition to DiseaseGTP PhosphohydrolasesHistiocytosis, Langerhans-CellHumansInfantMaleMAP Kinase Kinase 1Membrane ProteinsMiddle AgedMutation RatePhenotypeBRAF protein, humanGTP PhosphohydrolasesKIT protein, humanMAP2K1 protein, humanMAP Kinase Kinase 1Membrane ProteinsNRAS protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-kitBRAFKITLangerhans cell histiocytosisMAP2K1NRAS

Identifiers

PMID32372223
PMCPMC7581584
OpenAlexW3022892767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.